Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CD82 |
| Gene Name: | CD82 |
| Protein Full Name: | CD82 antigen |
| Alias: | C33; CD82 molecule; GR15; IA4; Inducible membrane protein R2; KAI1; Kangai 1 (suppression of tumorigenicity 6, prostate; Metastasis suppressor kangai 1; R2; R2 leukocyte antigen; SAR2; ST6; Suppression of tumorigenicity 6; Suppressor of tumorigenicity-6; Tetraspanin-27; TSPAN27; Tspan-27 |
| Mass (Da): | 29626 |
| Number AA: | 267 |
| UniProt ID: | P27701 |
| Locus ID: | 3732 |
| COSMIC ID: | CD82 |
| Gene location on chromosome: | 11p11.2 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19717 |
| Percent of cancer specimens with mutations: | 0.01 |
| Normal role description: | Clearly involved in suppressing tumour ability to metastasize in a variety of cancer models. Appears to be downstream from p53 and loss of p53 function may predispose to tumour progression via downregulation of CD82. CD82 inhibits metastatic potential via interaction with the DARC protein on vascular endothelium. CD82 also functions to downregulate the beta-catenin-reptin complex and loss of functional CD82 can promote oncogenesis via increased beta-catenin signalling. |